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Abstract
Peroxynitrite is a potent oxidant and nitrating species formed from the reaction between the free
radicals nitric oxide and superoxide. An excessive formation of peroxynitrite represents an
important mechanism contributing to cell death and dysfunction in multiple cardiovascular
pathologies, such as myocardial infarction, heart failure and atherosclerosis. Whereas initial works
focused on direct oxidative biomolecular damage as the main route of peroxynitrite toxicity, more
recent evidence, mainly obtained in vitro, indicates that peroxynitrite also behaves as a potent
modulator of various cell signal transduction pathways. Due to its ability to nitrate tyrosine
residues, peroxynitrite affects cellular processes dependent on tyrosine phosphorylation.
Peroxynitrite also exerts complex effects on the activity of various kinases and phosphatases,
resulting in the up- or downregulation of signalling cascades, in a concentration- and cell-
dependent manner. Such roles of peroxynitrite in the redox regulation of key signalling pathways
for cardiovascular homeostasis, including protein kinase B and C, the MAP kinases, Nuclear
Factor Kappa B, as well as signalling dependent on insulin and the sympatho-adrenergic system
are presented in detail in this review.
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2. INTRODUCTION: FORMATION, REACTIVITY AND CHEMICAL BIOLOGY
OF PEROXYNITRITE
Peroxynitrite is a strong biological oxidant and nitrating compound formed from the
extremely rapid, diffusion limited (rate constant k between 6.6 and 19 × 109M−1sec−1)
reaction between two parent radicals, the superoxide anion (O2.−) and nitric oxide (NO) (1).
The rate of this reaction is at least 3–8 times greater than the rate of O2.− decomposition by
superoxide dismutase (SOD, k=2.5 × 109M−1sec−1), indicating that NO has the ability to
drive O2.− away from its main detoxification pathway (1). The cellular sources of NO are
restricted to the various isoforms of NO synthases, whereas O2.− can arise from the
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mitochondrial electron transport chain, NADPH oxidase and xanthine oxidase (1, 2), as
shown in Figure 1. Further, NO synthase can also become an O2.− generator when it is
“uncoupled”, as may occur in conditions of oxidant stress or reduced substrate (L-arginine)
or cofactors (tetrahydrobiopterin) availability (3). Importantly, the reaction of NO with O2.−
essentially depends on the ratio of superoxide to NO rather than the net amount of these two
precursors, implying that peroxynitrite is generated whenever approximately equal, but not
necessarily augmented, fluxes of NO and O2.− are present (1).
Peroxynitrite easily crosses biological membranes, and despite a relatively short half-life
(~10 ms), it can interact with target molecules in adjacent cells within one or two cell
diameters (1, 2). It oxidizes target molecules either directly, through one or two-electron
oxidation processes, (most notably thiols and iron-sulfur centers in proteins), or indirectly,
via the generation of highly reactive radicals formed from the reaction of peroxynitrite with
carbon dioxide, (which generates CO3.− and NO2.), and from the homolysis of peroxynitrous
acid (ONOOH) into OH. and NO2. (1, 2). These radicals are strong one-electron oxidants
and NO2. can additionally trigger the nitration of tyrosine residues in proteins, forming 3-
nitrotyrosine (4), as detailed below. Nitrotyrosine can easily be detected, and thus is helpful
to assess the formation of peroxynitrite in biological systems (5), although it must be
stressed that nitrotyrosine may also be formed independently from peroxynitrite, following
the generation of NO2. by various heme-peroxidases (myeloperoxidase and eosinophil
peroxidase) in the presence of hydrogen peroxide (1, 6).
If formed in sufficient amounts to overcome cellular antioxidant defenses, peroxynitrite and
its secondary radicals will inflict various oxidative damage to proteins, lipids and DNA. In
turn these alterations inactivate metabolic enzymes, ionic pumps, and structural proteins,
disrupt cell membranes and break nucleic acids, resulting in the dysfunction of multiple
cellular processes and the induction of cell death through both apoptosis and necrosis,
depending on the level of peroxynitrite (1, 2), as shown in Figure 1. A major pathway of
peroxynitrite-dependent cytotoxicity is represented by the activation of the nuclear enzyme
poly (ADP-ribose) polymerase (PARP) in response to DNA damage, which may trigger cell
necrosis by ATP depletion, as indicated in figure 1 (see (7) for a detailed recent review on
this particular topics). There is now substantial evidence that these multiple pathways of
peroxynitrite-mediated cytotoxicity play key roles in the development and perpetuation of a
number of cardiovascular and non cardiovascular diseases, as extensively reviewed recently
(1, 2). A less well characterized consequence of peroxynitrite relies in the modulation of cell
signal transduction. Increasing experimental evidence, mainly obtained in cellular models,
indeed supports such novel roles of peroxynitrite and has changed our understanding of the
pathophysiolgical roles of this species, as will be presented in detail in this review.
3. REDOX REGULATION OF CELL SIGNALLING BY PEROXYNITRITE
3.1. Tyrosine nitration and phosphotyrosine signalling
Protein tyrosine nitration is a covalent modification resulting from the addition of a nitro (-
NO2) group onto one of the two equivalent ortho carbons of the aromatic ring of tyrosine
(4), which may produce three distinct effects on the affected proteins: loss of function, gain
of function, or no effect (5). Widespread tyrosine nitration occurs in cells during in vitro
exposure to peroxynitrite, affecting structural proteins, ion channels, metabolic enzymes,
and proteins involved in apoptosis, to name only a few (see (5, 8, 9) for recent reviews on
protein tyrosine nitration). The relevance of such observations in vivo remains, however, to
be established, given that the yield of nitrotyrosine formation under conditions of elevated
peroxynitrite generation in vivo (nitro-oxidative stress) remains largely smaller than what
can be achieved in vitro with direct peroxynitrite exposure. Indeed, only 1 to 10 residues of
tyrosine per 100,000 are found nitrated in plasma proteins under inflammatory conditions,
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such as those observed in cardiovascular disease, although up to 10 times more 3-NT can be
detected in tissues (9).
A major aspect of tyrosine nitration by peroxynitrite is the possibility of impairment of
cellular processes depending on the generation of phosphotyrosine (1), as initially
demonstrated in in vitro studies using various synthetic peptide models. For example, Tyr15
nitration of a synthetic peptide mimicking the tyrosine phosphorylation site of p34 cdc2 (a
cyclin-dependent kinase required for completion of mitosis) fully prevented its
phosphorylation by the Src kinase p56 Lck (10), while nitration of a single amino acid
residue in synthetic substrates for the tyrosine kinases p43v-alb and pp60src reduced their
phosphorylation by more than 50% (11). Similarly, peroxynitrite-induced tyrosine nitration
at Tyr686of a synthetic analogue of platelet-endothelial cell adhesion molecule 1 impaired its
src-dependent phosphorylation and its binding to the tyrosine phosphatase SHP-2 (12).
Further extending these observations, Saeki et al. showed that the peroxynitrite donor 3-
morpholinosydnonimine (SIN-1) triggered the nitration, while suppressing the
phosphorylation, of the focal adhesion kinase (FAK) p130cas in human neuroblastoma SH-
SY5Y cells, an effect abrogated by the tyrosine phosphatase inhibitor vanadate (13).
Interestingly, vanadate also prevented the cell death triggered by SIN-1, suggesting that
tyrosine nitration of p130cas might inhibit a key survival signalling pathway, possibly by
interfering with the assembly of focal adhesion complexes (14).
The hypothesis that tyrosine nitration would essentially inhibit phosphotyrosine-dependent
cell signaling has been largely reviewed following a series of investigations concluding that
peroxynitrite rather promoted the process of tyrosine phosphorylation in a variety of cell
types (15–23). Proposed mechanisms involve an imbalance between tyrosine
phosphorylation and desphosphorylation, related to the activation of tyrosine kinases or the
inhibition of tyrosine phosphatases, respectively, by peroxynitrite (1).
Firstly, Several receptor tyrosine kinases exhibit stimulated activity upon peroxynitrite
exposure, triggering downstream phosphotyrosine-dependent signalling, as shown for the
platelet-derived growth factor receptor (PDGFR) and the receptor for brain-derived
neurotrophic factor (TrkB) in murine fibroblasts (24, 25), as well as the Epidermal Growth
Factor Receptor (EGFR) in rat lung myofibroblasts (26). Secondly, peroxynitrite can
directly enhance the activity of the non receptor tyrosine kinase Src, a family of proteins
involved in signalling networks regulating cell metabolism, viability, proliferation,
differentiation and migration (27), and whose catalytic activity is tightly regulated by the
degree of phosphorylation of a specific C-terminal Tyr residue (Tyr527): phosphorylation of
this residue maintains the kinase inactive by inducing its interaction with an –SH2 domain
within the protein, whereas its dephosphorylation triggers kinase activation by removing this
interaction (28). Activation of Src by peroxynitrite, as reported in nervous cells (20, 29–31),
endothelial cells (15) and erythrocytes (18, 20–22), remains incompletely understood in
terms of molecular mechanism. However, according to Mallozzi et al, it might rely on the
formation of a putative nitrated peptides, able to displace phosphorylated Tyr527 from its
binding site in the SH2 domain (21, 32), thereby producing a conformational change
identical to that produced by Tyr527 dephosphorylation.
Thirdly, peroxynitrite may also enhance phosphotyrosine signalling by impairing the activity
of phosphotyrosine phosphatases. These proteins share a conserved cysteine residue within
their active site, which is extremely sensitive to peroxynitrite-mediated oxidation and
enzyme inactivation (19, 33–35). It has been proposed that, due to its structural similarities
with phosphate anions, peroxynitrite might be attracted within the active site of the
phosphatase, resulting in the oxidation of this critical cysteine-bound thiol and its
subsequent inactivation (35).
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In summary, at variance with the initial proposal that peroxynitrite would exclusively impair
phosphotyrosine-dependent signalling by nitrating tyrosine, it has become evident that
peroxynitrite may also upregulate such signalling depending on the cell type studied, the
particular signaling pathway under investigation, and especially, the concentration of
peroxynitrite used. Peroxynitrite has been generally associated with transient and reversible
upregulation of phosphotyrosine at relatively low concentrations (10–200 microM), whereas
higher peroxynitrite concentrations have been correlated with irreversible nitrotyrosine
formation and suppression of phosphotyrosine signalling due to direct competition between
nitration and phosphorylation of tyrosine. Such dichotomy has been well described in the
band-3 protein, a membrane anion-exchange protein that mediates signalling events
stimulating glycolytic activity in human erythrocytes (19). Relatively low peroxynitrite
concentrations (10–100 microM) activated band-3 tyrosine phosphorylation through an
inhibition of phosphotyrosine phosphatase, leading to GAPDH activation and lactate
production. In contrast, higher peroxynitrite concentrations (200–1000 microM) induced
band-3 tyrosine nitration and inhibited tyrosine phosphorylation, leading to irreversible
suppression of glycolysis.
3.2. Peroxynitrite-mediated regulation of individual cell signalling pathways
3.2.1. Akt/protein kinase B—PKB (Akt) is a serine-threonine protein kinase that
integrates cellular responses to growth factors and other extracellular signals, most
significantly insulin. Activation of PBK/Akt crucially depends on phosphatidyl-inositol-3
kinase (PI3K) signalling through generation of 3′-phosphorylated phosphoinositides (36).
PI3K, a member of the lipid kinase family, is composed of a catalytic subunit (p110) and an
adaptor/regulatory subunit (p85). Upon receptor tyrosine kinase activation, the SH2 domain
of PI3K associates with the receptor, triggering poly-phosphoinositides that activate target
proteins including PKB/Akt, which harbour the protein-lipid binding domain pleckstrin-
homology (PH) domain. Upon interaction with phosphoinositides, PKB/Akt translocates to
the cell membrane where it is phosphorylated and activated by 3-phosphoinositide-
dependent kinases 1 and 2 (PDK1 and PDK2). PKB/Akt then transits through the cytosol
and eventually to the nucleus to regulate the activity of many substrates that influence cell
survival, growth and differentiation (37). Akt plays essential roles in the cardiovascular
system, sustaining potent cardioprotective activities in most pathological cardiac conditions
(38), mediated by multiple downstream effectors, especially mTOR, glycogen-synthase
kinase 3 (GSK3) and Pim-1 (39, 40). Furthermore, the PI3K-PDK-Akt axis ultimately
culminates in the pleiotropic biological actions of insulin, notably in vascular function, by
promoting nitric oxide (NO) release by phosphorylating serine (Ser) 1177 of endothelial NO
synthase, thereby serving a critical role in the maintenance of physiological endothelial
function.
Discordant data have been reported regarding the regulation of Akt signalling by
peroxynitrite. Both authentic peroxynitrite and the peroxynitrite donor SIN-1 triggered PKB/
Akt phosphorylation and activation, as reflected by increased phosphorylation of the PKB/
Akt substrate GSK3 in human skin fibroblasts (24). Activation of PKB/Akt was here
dependent on PDGFR and PI3K, because it was effectively inhibited by the specific
inhibitors AG1295, respectively wortmannin and LY294002 (24). In a rat hepatoma cell
line, peroxynitrite induced PI3K activation and PKB/Akt phosphorylation, leading to the
activation of Nrf2/ARE transcription factor and the upregulated expression of the
detoxifying enzyme glutathione-S-transferase (41). A similar conclusion was reached by Li
et al, who demonstrated a peroxynitrite-dependent phosphorylation of Akt triggering the
activation of Nrf2/ARE, and the subsequent upregulation of the antioxidant and
cytoprotective enzyme heme-oxygenase-1 in neural cells, resulting in the limitation of
peroxynitrite-mediated apoptosis (42). The mechanisms underlying Akt activation by
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peroxynitrite in the above-mentioned studies has not been detailed, but two experimental
works suggest that such activation rests on an oxidative, but not a nitrative, type of
chemistry induced by peroxynitrite (43, 44).
In contrast with these findings, peroxynitrite inhibited Akt signalling in PC12 cells (45),
endothelial cells (46–49), and Raw 264.7 macrophages (50). Restricted interactions of PI3K
and phosphotyrosine proteins could account for these findings (51), since peroxynitrite
nitrates a critical tyrosine residue in the p85 regulatory subunit of PI3K, preventing its
association with the catalytic p110 subunit and subsequent PI3K activation (48, 50).
Furthermore, as recently shown by Song and co-workers, Akt inhibition by peroxynitrite
may depend on a complex cascade of signalling, whereby peroxynitrite would first enhance
the nuclear shuttling of the zeta isoform of protein kinase C, followed by the nuclear export
of the serine-threonine protein kinase and tumor suppressor LKB1, leading to the activation
of the lipid phosphatase PTEN (Phosphatase and TENsin homologue deleted on
chromosome 10), culminating into the impairment of PI3K/Akt signalling (46, 47). The
inhibition of Akt by peroxynitrite has been associated with two major consequences, the first
one being enhanced and accelerated apoptosis (46–48), notably in endothelial cells, the
second one being the inhibition of insulin signalling (46). Given the well-known increase of
vascular oxidative stress and peroxynitrite generation in diabetic vessels, these detrimental
actions of peroxynitrite on Akt may play a critical role in the development and perpetuation
of the endothelial dysfunction associated with diabetes (46, 52).
To sum up, peroxynitrite can either promote or inhibit the activation of the PI3K/PKB (Akt)
pathway by inducing oxidation and tyrosine nitration reactions, respectively. The prevailing
effect may depend on peroxynitrite concentrations, the cell type studied, and the chemical
microenvironement. The in vivo relevance of peroxynitrite in the regulation of the PI3K/Akt
pathway in the cardiovascular system remains to be addressed in future studies.
3.2.2. Mitogen-activated protein kinases—The mitogen-activated protein kinases
(MAPKs) are the most important family of serine-threonine kinases, upon which many other
signalling pathways converge. MAPKs are activated by dual phosphorylation at a specific
tripeptide motif, mediated by a conserved protein kinase cascade involving MAPK kinases
(MKK or MEK) and MAPK kinase kinases (MKKK or MEKK) (53). Upstream signalling
pathways triggering MKKK activation mainly depends on the activation of growth factor
receptors and small G-proteins such as Ras, Rac and Cdc42 (36, 53). The four major groups
of MAPKs are extracellular signal-regulated protein kinase (ERK1/2), p38 MAPK (alpha,
beta, ga,mma, delta), c-Jun NH2-terminal kinase (JNK1, 2 and 3) and big MAP kinase
(BMK or ERK5) (54, 55). MAP kinases become activated upon cell exposure to a wide
range of stimuli, notably including oxidants and particularly peroxynitrite, as presented in
the next sections.
3.2.2.1 Extracellular signal-regulated protein kinase (ERK): ERK plays central roles in
signalling pathways activated by certain growth factors such as EGF (through the activation
of EGFR, ras, Raf-1 kinase, and MEK1) (26). In addition, ERK can be activated by
extracellular stress stimuli, such as oxidants and free radicals (36). In the heart, ERK
represents a critical regulator of myocardial hypertrophy, as well as an important
cardioprotective signalling molecule in various forms of stresses associated with myocyte
apoptosis, eg myocardial ischemia-reperfusion and heart failure, as extensively reviewed in
(38, 55).
The mechanism underlying ERK activation by oxidative stress is unclear. Direct activation
of growth factor receptors, inhibition of MAPK phosphatases, and direct activation of ras,
which acts as an oxidative stress sensor, might contribute to ERK activation by oxidants.
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Data in isolated fibroblasts (26, 56), neutrophils (57, 58), endothelial and vascular smooth
muscle cells (59–61), neural cells (31, 62), cardiomyocytes (63) and whole lung tissue (64)
showed that, in addition to other known oxidants, peroxynitrite is also a powerful activator
of ERK. However, distinct mechanisms may account for this effect in different cell types.
Indeed, activation of ERK depended on EGFR, Src tyrosine kinase and calcium calmodulin
in PC12 cells (31), while requiring ras/Raf-1/MEK activation in human neutrophils (58). In
endothelial cells, peroxynitrite activated ERK following the direct oxidative S-
glutathiolation of p21ras at cysteine-118, leading to increase Raf-1 binding and downstream
activation of ERK (59, 60). In contrast to these findings, we reported in H9C2
cardiomyocytes that peroxynitrite-mediated activation of ERK, although dependent on Raf-1
and MEK, was not due to upstream activation of p21ras (63). To address the respective roles
of oxidation and nitration of tyrosine residues in peroxynitrite-mediated Raf-1/MEK/ERK
activation, we took advantage of the fact that epicatechin, a flavanol extracted from green
tea, inhibits tyrosine nitration much more efficiently than tyrosine oxidation. Our data
showed that epicatechin prevented peroxynitrite-mediated protein nitration but did not affect
ERK activation, indicating that oxidative chemistry of peroxynitrite primarily accounts for
ERK activation in this setting (63). However, alternate mechanisms appear relevant in other
cell types. For example, peroxynitrite-mediated ERK activation was entirely dependent on
tyrosine nitration of MEK in rat lung myofibroblasts (62). Although peroxynitrite triggered
EGFR and Raf-1 phosphorylation in these cells, this effect was dispensable for MEK/ERK
activation. In some cell systems, activation of ERK upon peroxynitrite exposure was
observed independently from any activation of the Raf-1/MEK pathway. Instead, it was
related to the upstream activation of a calcium-dependent PKC isoform in rat-1 fibroblasts,
and was due to the peroxynitrite-mediated release of Zinc from intracellular stores in
primary oligodendrocytes (62).
Downstream events induced by the activation of ERK in response to peroxynitrite have
remained poorly investigated so far. It has notably been associated with an enhancement of
apoptotic cell death in primary murine neurons and astrocytes (65, 66), as well as in human
neuroblastoma cells (67) and bronchial epithelial cells (68). A further consequence appears
to be the activation of polymorphonuclear cells (PMNs). Indeed, ERK activated upon
peroxynitrite exposure triggered the upregulation of beta2-integrin CD11b/CD18 in human
PMNs, increased their adhesion to the endothelium (58), and enhanced their production of
oxygen free radicals (57). Finally, the cascade peroxynitrite-p21ras-Raf-1-ERK (see above)
in endothelial cells (59, 60) has been associated with the concomitant prevention of Akt
activation in response to insulin (60), supporting its involvement in the resistance to insulin
observed in type II diabetes, as exposed in detail below.
3.2.2.2. c-Jun NH2-terminal kinase (JNK): JNK exists as three distinct isoforms (JNK-1, 2
and 3), activated in response to environmental stress stimuli, such as UV light, heat shock,
osmotic stress, inflammatory cytokines, mechanical stress, and oxidants. JNK is activated by
small G-proteins (ras/rac) through a signalling pathway that involves multiple MAPKKK,
MKK1 and MKK4. These kinases are linked to each other by scaffold proteins (such as
JIP-1) in specific signalling modules (69, 70). Activated JNK phosphorylates the proto-
oncogene c-jun, which forms both homodimers and heterodimers with c-fos, leading to the
activation of the AP-1 transcription factor. The JNK signalling pathway plays major roles in
inflammatory responses and apoptosis. In analogy to ERK and p38 MAPK, divergent data
link JNK activation to either cell death or survival in different cell types exposed to various
stress stimuli for varying periods of time (36, 69). With specific respect to the heart, we
recently provided evidence of a direct role of JNK as an effector of cardiac damage during
myocardial infarction, by showing that a specific peptide inhibitor of JNK reduced apoptosis
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and infarct size, while preventing myocardial dysfunction in rats exposed to myocardial
ischemia and reperfusion (71).
Free radicals and oxidant species such as H2O2 can inactivate specific JNK phosphatases
and activate upstream signalling molecules in the JNK signalling pathway (36). It is thus not
surprising that JNK activation in response to peroxynitrite has been reported in a variety of
cell types in vitro, including bronchial and alveolar lung cells (68, 72), rat cardiomyocytes
(63), vascular endothelial and smooth muscle cells (73–75), liver epithelial cells (76), rat
PC12 cells (77) and mouse fibroblasts (78). Peroxynitrite-mediated JNK activation has been
associated with apoptotic cell death in murine alveolar C10 cells, in which JNK was
activated upon the oxidation of the death receptor Fas. Peroxynitrite-mediated Fas oxidation
resulted into Fas aggregation and the recruitment of the downstream effector FADD (Fas-
associated death domain), finally converging to JNK-dependent apoptosis (72). In
cardiovascular tissues information on peroxynitrite and the JNK pathway is scarce. We
reported that cultured H9C2 cardiomyocytes display a strong phosphorylation of both JNK1
and JNK2 in the presence of graded concentrations of peroxynitrite, but the outcome of such
activation was not investigated in this study (63). In the vasculature, peroxynitrite-dependent
JNK activation has been shown to occur in endothelial cells exposed to laminar shear stress,
which is essential to prevent the development of atherosclerosis, suggesting that
peroxynitrite may represent a key molecular link between endothelial mechanical stress and
endothelial function (73).
3.2.2.3. p38 MAP kinase: p38 MAPK includes 5 isoforms (alpha, beta1, beta2, gamma and
delta) (α, β1, β2, γ and δ), at least, which are activated by environmental stress via upstream
MAPKKK, MKK3 and MKK6. In the heart, p38 can be protective or detrimental to myocyte
survival in a stressor-specific manner, exerts strong pro-inflammatory and negative inotropic
effects, and also appears to play a protective role against cardiac myocyte hypertrophy and
myocardial remodeling (see (55) for review). A further emerging function of p38 is
represented by the regulation of proliferation in terminally differentiated cardiomyocytes
(79).
The role of p38 alpha and beta isoforms in the regulation of cell survival under oxidative
stress conditions has been studied extensively, in part owing to the availability of specific
pharmacological inhibitors of these isoforms. Activation of p38 by various oxidant species
induces cell cycle arrest and apoptosis in many cell types (36), and the outcome appears
similar with peroxynitrite. Indeed, the later is a powerful trigger of p38 phosphorylation and
activation in a wide number of cell types, notably from cardiac (63), vascular (48, 73, 80)
and neural origin (31, 81–85). Upstream intermediates linking peroxynitrite and p38 appear
largely cell specific, and involved, for instance, phospholipase A2 in bronchial epithelial
cells (61), calcium-calmodulin kinase II and src in PC12 cells (31), or the release of zinc
ions (Zn++) from intracellular stores in neurons (84, 85). The latter mechanism was recently
demonstrated in a cellular system relevant to the pathogenesis of cerebral ischemia and
neurodegenerative diseases. These diseases are associated with excessive stimulation of N-
methyl-D-aspartate (NMDA) receptors, enhanced neuronal NO generation, and subsequent
toxicity. Addition of exogenous NO or NMDA (to increase endogenous NO) to
cerebrocortical neurons led to peroxynitrite formation and consequent Zn++ release from
intracellular stores. Free Zn++ induced respiratory block, mitochondrial permeability
transition and p38 activation, followed by cell volume loss and apoptotic cell death, which
were prevented in cells harboring a dominant-negative form of p38 (84, 85). Importantly,
peroxynitrite is known to release free Zn++ by efficiently oxidizing Zn++-sulfur bridges in
mitochondrial proteins (84) and cytosolic enzymes of various cell types (86, 87). This
suggests that the crosstalk between peroxnitrite, Zn++ and p38 observed in neurons might
also occur in cells from tissues other than the brain.
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3.2.3. Protein kinase C—PKC is a family of phospholipid-dependent serine/threonine
kinases that participate in many signalling pathways regulating cell growth and
differentiation, apoptosis, immune reactions and stress responses, especially to oxidative
stress (36, 88). PKC consists of 11 isoforms subdivided in three subgroups with distinct
mechanisms of activation: classical PKC isoforms (alpha, betaI, betaII, gamma) are
activated by both calcium and diacylglycerol, novel PKC isoforms (delta, epsilon, eta, theta)
are activated by diacylglycerol alone, and atypical PKC isoforms (lambda, iota, zeta) are
activated by certain lipids but neither diacylglycerol nor calcium. Phosphorylation-activation
of PKC induces its translocation to subcellular compartments, a process assisted by scaffold
proteins (receptors for activated c kinase; RACKs) (89).
The role of PKC isoforms in cardiovascular diseases has been extensively investigated in
recent years. Notably, it has been established that two calcium-insensitive PKC isoforms,
PKC delta and epsilon, play opposing roles in ischemia/reperfusion injury of the heart:
activation of PKCdelta during reperfusion triggers mitochondrial alterations leading to
apoptotic cell death, whereas activation of PKCepsilon before ischemia protects
mitochondrial function and diminishes apoptosis (90). In fact, activation of PKCepsilon
represents a central mechanism of the cardioprotection afforded by so-called ischemic
preconditioning, a brief sequence of short bouts of ischemia-reperfusion preceding a
sustained ischemic event. During IPC, PKCepsilon is activated and translocates to cardiac
mitochondria, resulting in the opening of mitoKATP (mitochondrial ATP-sensitive K+)
channels, the prevention of mitochondrial permeability transition pore opening, and
protection against apoptosis (90).
Past evidence had been obtained that NO plays a major role in the process of PKCepsilon
activation during ischemic preconditioning. Recent findings suggest that peroxynitrite,
rather than NO, may be responsible for this effect, as indicated by Balafanova et al. (91).
These authors demonstrated that stimulation of rat primary cardiomyocytes with an NO
donor resulted in PKCepsilon activation, tyrosine nitration of PKCepsilon, and increased
interaction of PKCepsilon to its anchoring protein RACK2. All these effects were
suppressed by the peroxynitrite scavenger ebselen. Furthermore, peroxynitrite directly
enhanced the binding of recombinant PKCepsilon and RACK2 in an in vitro assay.
Comparable effects were detected in the intact myocardium in an in vivo model of NO-
mediated cardioprotection in the rabbit, thereby delineating a novel signaling mechanism by
which NO activates PKCepsilon in the heart via the generation of peroxynitrite (91).
In blood vessels, classical PKC isoforms regulate an array of physiological functions, and
increased PKC activity (especially of the beta isoforms) has been associated with various
acute and chronic vascular stresses, including hypoxia, ischemia-reperfusion, mechanical
stress (most notably restenosis after angioplasty), atherosclerosis, and with diabetic vascular
complications (92, 93). Importantly, all these forms of vascular stresses are associated with
an enhanced formation of peroxynitrite in the vessel wall (1), and several line of evidence
support a possible link between peroxynitrite and PKC activation in such conditions.
In bovine pulmonary endothelial cells, nitration of PKCalpha, associated with both its
activation and translocation to the cell membrane occurs upon peroxynitrite stimulation.
This effect is responsible for the downstream activation of cytosolic phospholipase A2
(cPLA2) and an increased release of arachidonic acid from the cell, implying that
peroxynitite-dependent PKCalpha activation acts to modulate the production of vasoactive
mediators from the endothelium (94). Furthermore, in retinal endothelial cell monolayers
incubated with either high glucose or advanced glycation end-products, peroxynitrite
formation occurs, leading to PKC activation and an increased permeability of the
monolayers to radiolabelled iodide, substantiating an important role of peroxynitrite-PKC
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signaling in altering normal endothelial physiology (95). Finally, peroxynitrite-mediated
PKC activation has also been advocated to be involved in the development of vascular
tolerance to nitroglycerin, a phenomenon which describes the progressive reduction of the
vasodilating properties of nitrogycerin upon repeated exposure. Indeed, tolerance of rat
aortic rings to nitroglycerine can be similarly prevented by the PKC inhibitor chelerythrine
and by the peroxynitrite scavenger uric acid, whereas in bovine endothelial cells, exposure
to nitroglycerin triggers the generation of peroxynitrite together with the activation and
translocation of the two PKC isoforms alpha and epsilon (96).
3.2.4. Nuclear factor kappa B (NFkappaB)—The NFkappaB family of dimeric
transcription factors regulates the expression of many genes involved in immune response,
inflammation and cytoprotection from environmental stress. NFkappaB family members
include p50 and p52 (as well as their p100 and p105 precursors), p65 (RelA), RelB and c-
Rel. Under basal conditions, NFkappaB transcription factors are bound to inhibitory
IkappaB proteins and sequestered in the cytoplasm. NFkappaB activation depends upon
IkappaB phosphorylation and recognition by ubiquitinating enzymes. Proteasomal
degradation of IkappaB proteins induces the release and nuclear translocation of IkappaB-
bound NFkappaB transcription factors, which trigger the expression of target genes (see (97,
98). IkappaB proteins are phosphorylated by a protein kinase complex, IkappaB kinase
(IKK), which is composed of two catalytic subunits, IKKalpha and IKKbeta, and a
regulatory subunit, IKKgamma or NEMO (for review see (98). Many NFkappaB activation
pathways converge on IKKalpha and IKKbeta. Inflammatory stimuli such as tumour
necrosis factor alpha (TNFalpha) and lipopolysaccharides (LPS) trigger rapid NFkappaB
activation in an IKKbeta-dependent manner (canonical pathway). Alternatively, a subset of
TNF family members can induce the activation of a specific form of NFkappaB by a slower
process dependent on the IKKalpha subunit (noncanonical pathway) (99).
Experimental evidence supports a pivotal role of NFkappaB in the pathophysiology of major
cardiac diseases, including myocardial infarction and heart failure. In animal models of
myocardial ischemia-reperfusion, several strategies inhibiting NFkappaB reduced infarct
size and post-infarction myocardial inflammation (100–102). NFkappaB inhibition has also
been associated with an attenuated myocardial hypertrophy induced by chronic angiotensin
II infusion or aortic banding in the mouse (103, 104). More importantly, in murine models
of heart failure after myocardial infarction, p50 KO mice are protected from cardiac
remodeling and left ventricular dysfunction (105, 106). Comparable results have been
obtained using a strategy of myocardial overexpression of IkappaBalpha by adenovirus-
mediated transfection in rats (107). In humans, myocardial tissue from patients with
congestive heart failure exhibits a robust activation of IKK and NFkappaB DNA binding, as
well as an increased expression of genes regulated by NFkappaB, such as cyclo-oxygenase
II, iNOS, TNFalpha and adhesion molecules, supporting the involvement of NFkappaB in
the process of cardiac remodeling in chronic heart failure (108–110).
Overall, reactive oxygen species (ROS) appear to favour NFkappaB activation (111), but the
specific role of peroxynitrite in this regard is incompletely understood. A series of
experiments performed in human polymorphonuclear cells (PMNCs) indicated that exposure
to exogenous peroxynitrite, as well as induction of endogenous peroxynitrite generation by
LPS, cytokines or Toll-like receptor (TLR)-9, activated NFkappaB, leading to an increase in
IL-8 secretion (112–115), implying that peroxynitrite may amplify neutrophil-dependent
responses during inflammation in an NFkappaB–dependent manner. Also, micromolar
concentrations of peroxynitrite triggered NFkappaB activation, along with TNFalpha and
IL-6 production in mononuclear cells, an effect proposed to depend on the nitration of
IkappaB at Tyr42, triggering its proteasomal degradation (116). By the same token,
Yakovlev et al. recently reported that nitration of IkappaB on Tyr181 was sufficient to
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provoke its dissociation from NFkappaB and to trigger its activation independently from
serine phosphorylation (117). A similar mechanism has further been proposed by Bar-Shai
and Reznick, investigating the effects of peroxynitrite on NFkappaB activation in skeletal
muscle (118, 119).
At variance with these findings, two recent reports unveiled suppressive effects of
peroxynitrite on NFkappaB activation in different experimental systems. Data by Park et al
(120) showed that peroxynitrite inhibited both constitutive and induced NFkappaB activities
in P19, SH-SY5Y and HEK293 cells via p65 nitration at Tyr66 and Tyr152, leading to p65
destabilisation and nuclear export. In line with these findings, we have shown that a short
exposure of cardiac H9c2 cells or endothelial EAHY-926 and HMEC-1 cells to peroxynitrite
completely inhibited IKKbeta phosphorylation and NFkappaB activation in response to LPS
or inflammatory cytokines (121). These effects were accompanied by an increase in
IKKalpha phosphorylation, consistent with differential regulation of IKKalpha and IKKbeta
by peroxynitrite. Together, these findings provide initial evidence for the unforeseen concept
that peroxynitrite may downregulate inflammatory responses under certain conditions. The
in vivo relevance of this mechanism needs now to be investigated.
3.2.5 Insulin signalling—As mentioned previously, insulin, in addition to its metabolic
effects, plays a critical role in the maintenance of physiological endothelial function through
its ability to stimulate NO release via a cascade of signalling, involving activation of the
PI3K-Akt axis and the downstream serine phosphorylation of endothelial NO synthase.
Conversely, peroxynitrite inhibits PKB/Akt signalling in endothelial cells (see above), and
might thus disrupt this essential vasoprotective role of insulin, a hypothesis elegantly
confirmed in a recent study by Song et al. (46). These authors showed that exposure of
cultured human umbilical vein endothelial cells (HUVECs) to peroxynitrite or high glucose
significantly inhibited both basal and insulin-stimulated serine phosphorylation of PKB/Akt
and its activation. Using small interfering (si) RNA technologies, they could demonstrate
that these changes were related to an increased phosphorylation and activity of Phosphatase
and TENsin homologue deleted on chromosome 10 (PTEN), elicited by the tumor
suppressor LKB1, eventually leading to apoptotic cell death. In vivo, the aortas of diabetic
mice exhibited increased levels of nitrotyrosine, together with increased phosphorylation of
PTEN and LKB1, but reduced PKB/Akt phosphorylation. Administration of PTEN-specific
siRNA reversed PKB/Akt inhibition and mitigated apoptosis in diabetic mouse aortas. These
findings therefore suggest that hyperglycaemia may promote apoptosis in endothelial cells
through PKB/Akt downregulation, via a peroxynitrite-mediated, LKB1-dependent PTEN
activation (46).
A further mechanism of peroxynitrite-mediated alteration of insulin signalling has been
unveiled by Nomiyama et al, who reported that peroxynitrite inhibited insulin-stimulated
glucose uptake in preadipocyte-derived 3T3-L1 cells by reducing insulin receptor
substrate-1 (IRS-1) protein levels and associated PI3K activity, upstream of Akt/PKB (122).
The mechanism of this effect was worked-up in rat fibroblasts expressing human insulin
receptors, and exposed to the peroxynitite generator SIN-1. Using mass spectrometry, it was
found that peroxynitrite induced at least four nitrated tyrosine residues in rat IRS-1,
including Tyr939, which is critical for the association of IRS-1 with the p85 subunit of PI3K.
Thus, peroxynitrite reduces the level of IRS-1, while inducing at the same time its tyrosine
nitration, thereby impairing insulin signalling on Akt/PKB.
2.2.6. Sympatho-adrenergic signalling—The catecholamines epinephrine (or
adrenaline) and norepinephrine (or noradrenaline) are key modulators of cardiac and
vascular function, whose biological effects are mediated by adrenergic receptors, which
exist as nine distinct subtypes, termed alpha1A, alpha1B, alpha1D, alpha2A, alpha2B, alpha2C,
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beta1, beta2 and beta3. All these receptors are G-protein-coupled receptors which, upon
activation, stimulate (Gs-proteins) or inhibit (Gi-proteins) the signalling cascade adenylyl
cyclase-protein kinase A, or activate (Gq-proteins) another effector enzyme, phospholipase
C (PLC) (123). Among the alpha receptors, type 1 receptors mainly mediate smooth muscle
contraction and cellular hypertrophy, whereas type 2 receptors, located on presynaptic
noradrenergic nerve terminals, inhibit the release of catecholamines, and thus are critical to
regulate sympathetic output (124). Regarding the subtypes of beta receptors, beta1 and beta2
exert positive inotropic effects on the heart and relax vascular smooth muscle, while the
beta3 subtype is responsible for a negative inotropic effect in the heart (125).
Experimental studies have indicated that both alpha- and beta-adrenoceptors are biological
targets of peroxynitrite. Benkusky et al. examined the effects of systemic administration of
peroxynitrite on the changes in arterial pressure and vascular resistances produced by the
alpha-adrenergic catecholamines epinephrine, norepinephrine, and phenylephrine in
anesthetized rats, and found that it markedly inhibited both pressor and vaosonstrictor
responses to these agonists (126). This observation was extended by Takakura et al., who
performed binding experiments of (3H) prazosin and norepinephrine in Chinese hamster
ovary cells expressing recombinant human alpha adrenoceptors. Peroxynitrite significantly
reduced the binding capacity of both alpha1A and alpha1D-adrenoceptors in a concentration-
dependent manner, and attenuated noradrenalin-stimulated increases in intracellular Ca2+
concentration in cells expressing alpha1A, and alpha1D-, but not alpha1B-adrenoceptors.
These effects translated into a markedly reduced contractile response to norepinephrine of
isolated rat aortic strips (127). Although the underlying mechanism was not anticipated in
these studies, the negative effect of peroxynitrite on alpha-adrenoceptors suggests that it
may be involved in pathological states associated with reduced vascular contractility, e.g.
septic shock. The latter hypothesis is further reinforced by the reported ability of
peroxynitrite to directly inactivate catecholamines by oxidative modifications (128, 129).
With respect to beta-adrenoceptors, Lewis and co-workers recently showed that
peroxynitrite could block the effects of the beta agonist isoproterenol on beta1 and beta2-,
but not beta3 adrenoceptors (130). Since beta1 and beta2, but not beta3-adrenoceptors
contain extracellular tyrosine residues susceptible to nitration reactions, these observations
suggest that peroxynitrite impairs beta-adrenergic responses by nitrating tyrosine resides
within beta1 and beta2 adrenoceptors (130), a mechanism which has been proposed to
participate to the blunted response of the myocardium to beta-adrenoceptor stimulation in
patients with chronic heart failure (131, 132).
4. CONCLUSIONS AND PERSPECTIVES
Emerging evidence presented in this review indicates that peroxynitrite exhibits the
distinctive features of a signalling molecule in vitro, leading to either activation or inhibition
of a wealth of cellular signal transduction pathways, whose dysregulation plays key roles in
the development and perpetuation of cardiovascular pathologies. Whereas early studies were
based on the concept that peroxynitrite, owing to its ability to nitrate tyrosine residues in
proteins, would principally behave as an inhibitor of phosphotyrosine-dependent cell
signalling, it rapidly turned out that, in many instances, peroxynitrite could upregulate
multiple signalling cascades by inhibiting protein phosphatases and activating many
different protein kinases. In spite of this experimental evidence, several limitations presently
hinder the precise interpretation of these findings. First, given their conspicuous cell
specificity, any generalization of these effects would be extremely speculative. Second, the
likely cellular compartmentalization of the signalling response triggered by peroxynitrite
remains essentially unexplored. Third, the scarcity of in vivo results that confirm (or
disagree with) in vitro data indicate that the relevance of peroxynitrite-dependent signalling
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in pathological states remains to be precised. Obviously, there is the need for further studies
exploring signalling roles of peroxynitrite and its mechanisms both at the cell level and in
the intact organism. Improving our understanding of such aspects of peroxynitrite biology in
the pathogenesis of cardiovascular diseases will pave the way to the discovery of novel
efficient drugs in the future.
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Formation, chemical biology and major targets of peroxynitrite-induced cellular toxicity.
Peroxynitrite is formed from the reaction between the free radicals nitric oxide (NO) and
superoxide (O2.−). NO arises from the oxidation of L-arginine by various NO synthases
isoforms (endothelial-eNOS-, inducible-iNOS-, and neuronal-nNOS). In turn, NO activates
soluble guanylyl-cyclase (sGC) to form the second messenger cyclic GMP (cGMP), which
mediates many physiological and cytoprotective actions of NO, as indicated by the blue
arrows. O2.− is formed in the mitochondrion, as well as by the enzymatic activities of
xanthine oxidase, NADPH oxidase, and uncoupled eNOS. O2.− may be transformed by
superoxide dismutase (SOD) into hydrogen peroxide (H2O2). When equimolar fluxes of NO
and O2.− occur in close proximity, they react immediately to yield peroxynitrite (ONOO−).
In turn peroxynitrite triggers a myriad of cytotoxic effects including lipid peroxidation,
protein nitration and oxidation, DNA oxidative damage, activation of matrix
metalloproteinases (MMP), and inactivation of a series of enzymes (red arrows). If severe
enough to overcome cellular antioxidant defenses, the biomolecular injuries initiated by
peroxynitrite can damage mitochondria, leading to the collapse of the mitochondrial
transmembrane potential (ΔΨ) followed by the release of proapoptotic factors (cytochrome
C -cyt C- and apotosis inducing factor-AIF) and the induction of apoptosis, and can also
result in the activation of the nuclear enzyme poly (ADP-ribose) polymearse (PARP).
Activated PARP consumes nicotinamide (NAD) to build-up poly (ADP-ribose) polymers
(PAR), which are themselves rapidly metabolized by the activity of poly (ADP-ribose)
glycohydrolase (PARG). Some free PAR may exit the nucleus and travel to the
mitochondria, where they amplify the mitochondrial efflux of AIF. Overactivation of PARP
results in massive NAD consumption and collapse of cellular ATP, leading to cell necrosis.
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Major signaling pathways influenced by peroxynitrite. The signs +/- indicate whether the
particular signaling protein is inhibited or activated (or both) by peroxynitrite. EGFR,
epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; TrkB,
receptor for brain-derived neurotrophic factor; JNK, c-jun-NH2-terminal kinase; ERK,
extracellular-regulated kinase; p38, p38 MAP kinase; PI3K/PKB, phosphatidylinositol 3-
kinase/protein kinase B; PKC, protein kinase C; NFκB, nuclear factor kappa B
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